Bristol-Myers Squibb Stock Slides -8.1% With A 7-Day Losing Spree
Bristol-Myers Squibb (BMY) – a biopharmaceutical company developing treatments for cancer and diseases – hit a 7-day losing streak, with cumulative losses over this period amounting to -8.1%. The company’s market cap has crashed by about $10 Bil over the last 7 days and currently stands at $113 Bil.
Is this an opportunity or a trap? There is a near-equal mix of good and bad in BMY stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (For details, see Buy or Sell BMY).
But here is the interesting part. You are reading about this -8.1% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.
Returns vs S&P 500
- 11 Large Cap Stocks Just Made New 52-Week Highs
- 4 S&P 500 Stocks Hit 52-Week Highs On Friday
- Where The Buying Ran Strongest: 8 S&P 500 Stocks At 52-Week Highs
- The 52-Week-High List: 32 S&P 500 Names On Friday
- How Bristol-Myers Squibb Stock Gained 30%
- What Is Happening With Bristol-Myers Squibb Stock?
The following table summarizes the return for BMY stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | BMY | S&P 500 |
|---|---|---|
| 1D | -0.9% | 0.2% |
| 7D (Current Streak) | -8.1% | 2.8% |
| 1M (21D) | -5.0% | 8.7% |
| 3M (63D) | -7.4% | 6.4% |
| YTD 2026 | 5.5% | 8.3% |
| 2025 | 0.1% | 16.4% |
| 2024 | 15.8% | 23.3% |
| 2023 | -26.1% | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 25 S&P constituents with 3 days or more of consecutive gains and 97 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 7 | 76 |
| 4D | 7 | 9 |
| 5D | 4 | 3 |
| 6D | 5 | 3 |
| 7D or more | 2 | 6 |
| Total >=3 D | 25 | 97 |
Key Financials for Bristol-Myers Squibb (BMY)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $48.3 Bil | $48.2 Bil |
| Operating Income | $5.9 Bil | $13.7 Bil |
| Net Income | $-8.9 Bil | $7.1 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $12.5 Bil | $11.5 Bil |
| Operating Income | $2.8 Bil | $3.4 Bil |
| Net Income | $1.1 Bil | $2.7 Bil |
The losing streak BMY stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.